AVDL Valuation

Avadel Pharmaceuticals PLC

Add to Watchlist

Advanced Chart

16.230

+0.57(3.640%)1D

Overview
Forecast
Valuation
Earnings

AVDL Relative Valuation

AVDL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AVDL is overvalued; if below, it's undervalued.

Historical Valuation

Avadel Pharmaceuticals PLC (AVDL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.77 is considered Undervalued compared with the five-year average of 148.01. The fair price of Avadel Pharmaceuticals PLC (AVDL) is between 51.43 to 60.49 according to relative valuation methord. Compared to the current price of 16.23 USD , Avadel Pharmaceuticals PLC is Undervalued By 68.44%.

Relative Value

Fair Zone

51.43-60.49

Current Price：16.23

68.44%

Undervalued

34.75

Trailing

Forward

24.55

EV/EBITDA

Avadel Pharmaceuticals PLC. (AVDL) has a current EV/EBITDA of 24.55. The 5-year average EV/EBITDA is 22.46. The thresholds are as follows: Strongly Undervalued below -1.98, Undervalued between -1.98 and 10.24, Fairly Valued between 34.68 and 10.24, Overvalued between 34.68 and 46.90, and Strongly Overvalued above 46.90. The current Forward EV/EBITDA of 24.55 falls within the Historic Trend Line -Fairly Valued range.

27.10

EV/EBIT

Avadel Pharmaceuticals PLC. (AVDL) has a current EV/EBIT of 27.10. The 5-year average EV/EBIT is 96.10. The thresholds are as follows: Strongly Undervalued below -182.73, Undervalued between -182.73 and -43.32, Fairly Valued between 235.51 and -43.32, Overvalued between 235.51 and 374.92, and Strongly Overvalued above 374.92. The current Forward EV/EBIT of 27.10 falls within the Historic Trend Line -Fairly Valued range.

4.69

Avadel Pharmaceuticals PLC. (AVDL) has a current PS of 4.69. The 5-year average PS is 4.79. The thresholds are as follows: Strongly Undervalued below 1.46, Undervalued between 1.46 and 3.12, Fairly Valued between 6.45 and 3.12, Overvalued between 6.45 and 8.11, and Strongly Overvalued above 8.11. The current Forward PS of 4.69 falls within the Historic Trend Line -Fairly Valued range.

23.96

P/OCF

Avadel Pharmaceuticals PLC. (AVDL) has a current P/OCF of 23.96. The 5-year average P/OCF is 34.54. The thresholds are as follows: Strongly Undervalued below -74.42, Undervalued between -74.42 and -19.94, Fairly Valued between 89.01 and -19.94, Overvalued between 89.01 and 143.49, and Strongly Overvalued above 143.49. The current Forward P/OCF of 23.96 falls within the Historic Trend Line -Fairly Valued range.

24.17

P/FCF

Avadel Pharmaceuticals PLC. (AVDL) has a current P/FCF of 24.17. The 5-year average P/FCF is 30.72. The thresholds are as follows: Strongly Undervalued below 5.01, Undervalued between 5.01 and 17.86, Fairly Valued between 43.58 and 17.86, Overvalued between 43.58 and 56.43, and Strongly Overvalued above 56.43. The current Forward P/FCF of 24.17 falls within the Historic Trend Line -Fairly Valued range.

Avadel Pharmaceuticals PLC (AVDL) has a current Price-to-Book (P/B) ratio of 16.71. Compared to its 3-year average P/B ratio of 15.49 , the current P/B ratio is approximately 7.88% higher. Relative to its 5-year average P/B ratio of 15.49, the current P/B ratio is about 7.88% higher. Avadel Pharmaceuticals PLC (AVDL) has a Forward Free Cash Flow (FCF) yield of approximately 0.35%. Compared to its 3-year average FCF yield of -6.21%, the current FCF yield is approximately -105.58% lower. Relative to its 5-year average FCF yield of -6.21% , the current FCF yield is about -105.58% lower.

16.71

P/B

Median3y

15.49

Median5y

15.49

0.35

FCF Yield

Median3y

-6.21

Median5y

-6.21

Competitors Valuation Multiple

The average P/S ratio for AVDL's competitors is 54.78, providing a benchmark for relative valuation. Avadel Pharmaceuticals PLC Corp (AVDL) exhibits a P/S ratio of 4.69, which is -91.44% above the industry average. Given its robust revenue growth of 64.15%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AVDL.O

Avadel Pharmaceuticals PLC

Viridian Therapeutics Inc

Performance Decomposition

Market capitalization of AVDL increased by 19.63% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -261.03 to -517.07.

The secondary factor is the Revenue Growth, contributed 64.15%to the performance.

Overall, the performance of AVDL in the past 1 year is driven by P/E Change. Which is more unsustainable.

64.15%

41.50M → 68.13M

Revenue Growth

-142.61%

-33.30 → 14.19

Margin Expansion

98.09%

-261.03 → -517.07

P/E Change

19.63%